Grayanotoxin LD50: Lethal Dose Data, Route Effects, and What Animal Studies Cannot Tell You About Human Risk

The LD50, lethal dose 50 percent, is the amount of a substance required to kill 50 percent of a test population under specified experimental conditions. It is a standard measure of acute toxicity used to compare compounds and establish hazard classifications. For grayanotoxin, published LD50 data exist in mice across several isoforms and routes of administration.

The question is common and reasonable. The useful answer requires specifying four things: which isoform (GTX I, II, or III), which species (the published values are all from mice), which route of administration (intraperitoneal injection or oral), and what extrapolation caveats apply before that number means anything for a human consuming honey. All four matter, and this article addresses each.

It also addresses the separate question of what the human clinical case record tells us about lethality thresholds, which is, for practical purposes, the more relevant dataset.

Contents

1. The Published LD50 Data: What the Animal Studies Show
2. Reading the table correctly – two critical observations
3. Why IP Injection LD50 Values Cannot Be Applied to Oral Honey Consumption
4. Why No Human LD50 Exists or Can Be Established
5. What the Clinical Case Record Says About Human Lethality
6. Translating the LD50 Data to a Honey Consumption Context
7. The Isoform Question for Risk Assessment
8. What We Don’t Know Yet
9. Summary
10. Sources

The Published LD50 Data: What the Animal Studies Show

Grayanotoxin LD50 data come from mouse studies published between 1971 and 1979, mostly using intraperitoneal (IP) injection (Scott et al. 1971; Fukuda et al. 1974; Hikino et al. 1976, 1979). EFSA’s 2023 assessment tabulates them, and found no studies deriving LD50 values in rats (EFSA 2023).

Reading the table correctly – two critical observations

First, the oral LD50 values in mice were 3.8 times the IP value for GTX I and 5.8 times for GTX III, in two studies by the same group using the same source and vehicle (Hikino et al. 1976, 1979, as reported by EFSA 2023). Direct injection into the peritoneal cavity bypasses gastrointestinal absorption, first-pass hepatic metabolism, and the diluting effect of stomach contents. IP injection delivers the compound directly to the systemic circulation at high bioavailability. Oral consumption from a honey matrix is a different exposure pathway entirely.

Second, GTX II, with IP LD50 values of 10 to 26.1 mg/kg, is about an order of magnitude less potent than GTX I and III (EFSA 2023), so not all grayanotoxin isoforms carry equivalent toxicity. A COA reporting total GTX without distinguishing isoforms combines values with very different clinical weights.

Why IP Injection LD50 Values Cannot Be Applied to Oral Honey Consumption

The most common error in the discussion of grayanotoxin toxicity is applying IP injection LD50 values to scenarios involving oral consumption of honey. The two exposure routes are pharmacokinetically incomparable.

Bioavailability

Intraperitoneal injection delivers the compound to the highly vascularised peritoneal cavity, from which absorption into systemic circulation is rapid and near-complete. Oral ingestion requires the compound to survive the gastric environment, cross the intestinal mucosa, survive first-pass hepatic metabolism, and enter systemic circulation in whatever fraction survives those steps. For many lipophilic compounds, oral bioavailability is a fraction of IP bioavailability.

No formally published oral bioavailability study for GTX I or GTX III from a honey matrix in humans exists. Extrapolating the IP LD50 to an oral consumption scenario requires assuming near-complete bioavailability, an assumption that is almost certainly incorrect and that systematically overestimates the toxicity of oral consumption relative to IP injection.

The honey matrix effect

GTX in mad honey is not a purified compound in a neutral vehicle. It is embedded in a complex carbohydrate-rich viscous matrix containing water, sugars, organic acids, proteins, and other secondary metabolites. The absorption kinetics of GTX from this matrix differ from those of purified GTX in aqueous solution. The matrix may slow gastric emptying, affect intestinal absorption, and alter the time-to-peak-blood-concentration profile.

No validated human blood threshold exists to test this against: the six-patient blood-level estimates cited by Aryal (2025) come from people who drank a Rhododendron liqueur, and EFSA did not use them because of inconsistencies in how the concentrations and doses were reported (EFSA 2023).

Species differences

Mouse and rat pharmacokinetics, receptor densities, cardiac conduction system properties, and metabolic enzyme expression differ from each other and from humans. Species extrapolation from rodent IP LD50 to human oral LD50 involves two separate and compounding uncertainties: species difference and route difference. Any figure attempting to state a human LD50 from these data is combining multiple unstated assumptions into a single number presented with more precision than the underlying evidence warrants.

Why No Human LD50 Exists or Can Be Established

No controlled human LD50 study for grayanotoxin exists or could ethically be conducted. Establishing an LD50 requires exposing a population to graduated doses and observing mortality at each level. This is acceptable in rodent models as part of standard toxicological risk assessment. It is not acceptable in humans.

What the human evidence base contains instead is a different kind of data: the clinical case record. Hundreds of documented cases of grayanotoxin poisoning from Turkey and Nepal, with intake amounts estimated retrospectively and clinical outcomes recorded, provide an upper-bound dataset for human acute toxicity. The record documents what amounts caused cardiovascular presentations requiring hospital treatment. It does not document what amounts were lethal in untreated cases, because almost all documented cases received emergency treatment.

What the Clinical Case Record Says About Human Lethality

Documented fatal outcomes from standard Rhododendron-derived grayanotoxin poisoning are rare in the modern case literature. No deaths were reported among the 1,199 cases reviewed by Silici and Atayoglu (2015), and EFSA notes that no fatalities from Rhododendron honey poisoning have been reported in modern times, although it may be life-threatening in people with cardiac complications (EFSA 2023).

Because modern treated cases have not been fatal, the case record cannot show a lethal intake for humans. What it shows is that serious effects such as complete AV block and severe hypotension respond to treatment: saline infusion and atropine alone are almost always successful (Gunduz et al. 2008).

Translating the LD50 Data to a Honey Consumption Context

A rough order-of-magnitude translation is useful, not as a precise risk threshold, but as a way of understanding the scale of the difference between experimental toxicology and real-world consumption.

Scaling a rodent LD50 to a person is not meaningful. The mouse oral LD50 values of 4.9 and 5.1 mg/kg come from plant extracts given in a gum arabic solution, not from honey (Hikino et al. 1979). EFSA’s reference point for acute effects in people is 15.3 micrograms per kg of body weight for GTX I and III combined, based on reduced heart rate in rats, which is more than 300 times lower (EFSA 2023).

Case reports describe poisoning after as little as one teaspoon of honey (Ullah et al. 2018). Grayanotoxin causes serious cardiovascular effects far below any lethal dose, which is why the LD50 is a poor guide to human risk.

The Isoform Question for Risk Assessment

Different batches of mad honey contain different ratios of GTX I, GTX II, and GTX III. A COA reporting only total grayanotoxin aggregate compounds with substantially different LD50 values (GTX I about 1.3 mg/kg versus GTX II 10 to 26 mg/kg in mice by IP injection; EFSA 2023) into a single figure. For comprehensive risk characterisation, isoform-specific quantification matters.

In practice, GTX I and GTX III are the primary clinical concern because they are both present in significant quantities in active mad honey and both have IP LD50 values of about 0.8 to 1.5 mg/kg in mice (EFSA 2023). GTX II, where it has been measured, occurs at low levels and is not a primary acute toxicity driver.

LC-MS/MS, the method Ahn et al. (2022) used to measure GTX I and GTX III separately, is the standard for COA purposes because it quantifies the isoforms individually rather than as a total (EFSA 2023).

What We Don’t Know Yet

No oral bioavailability study for GTX I or GTX III from a honey matrix in any species exists in the peer-reviewed literature. The oral LD50 values cited above come from extracts given in a gum arabic solution (Hikino et al. 1979), not from honey. The actual bioavailability from honey may differ due to the matrix effects described above.

No human pharmacokinetic study exists. The absorption, distribution, metabolism, and elimination parameters for GTX in humans are not established. The interaction between GTX isoforms in mixed exposure, as occurs in real honey consumption, is not systematically studied. Most LD50 studies used single isoforms isolated from plant extracts, often of unreported purity (EFSA 2023).

Summary

Grayanotoxin LD50 data come from rodent models using intraperitoneal injection. GTX I has an IP LD50 of about 1.3 mg/kg in mice, and GTX III about 0.8 to 0.9 mg/kg. GTX II is about an order of magnitude less toxic, with IP LD50 values of 10 to 26 mg/kg (EFSA 2023). These values cannot be directly applied to oral honey consumption: IP injection bypasses gastrointestinal absorption and first-pass metabolism; the honey matrix affects absorption kinetics; and species extrapolation introduces further uncertainty. In mice the oral LD50 is 3.8 to 5.8 times the IP value (EFSA 2023).

No human LD50 data exists, and none can be ethically established. The clinical case record, in which poisoning has followed as little as one teaspoon of honey (Ullah et al. 2018), is the more relevant reference point for human risk. No deaths were reported among 1,199 published cases (Silici and Atayoglu 2015). The clinical risk is AV block and hemodynamic compromise that becomes lethal without treatment, not acute compound toxicity at a pharmacological LD50 threshold.

 

Sources

• Ahn SY, Kim S, Cho H (2022), Determination of Grayanotoxin I and Grayanotoxin III in mad honey from Nepal using liquid chromatography-tandem mass spectrometry. Analytical Science and Technology 35(2):82-91.
• Aryal M (2025), Grayanotoxins in Mad Honey: Mechanisms of Toxicity, Clinical Management, and Therapeutic Implications. Journal of Applied Toxicology 45(11):2240-2256.
• EFSA CONTAM Panel (2023), Risks for human health related to the presence of grayanotoxins in certain honey. EFSA Journal 21(3):7866.
• Fukuda H, et al. (1974), Structure-Activity Relationship of Lyoniol-A and Related Compounds in Association with the Excitatory Effect on Muscle Spindle Afferents. Chemical and Pharmaceutical Bulletin 22(4):884-888.
• Gunduz A, et al. (2008), Clinical review of grayanotoxin/mad honey poisoning past and present. Clinical Toxicology 46(5):437-442.
• Hikino H, et al. (1976), Structure-activity relationship of ericaceous toxins on acute toxicity in mice. Toxicology and Applied Pharmacology 35(2):303-310.
• Hikino H, et al. (1979), Subchronic toxicity of ericaceous toxins and Rhododendron leaves. Chemical and Pharmaceutical Bulletin 27(4):874-879.
• Jansen SA, et al. (2012), Grayanotoxin Poisoning: ‘Mad Honey Disease’ and Beyond. Cardiovascular Toxicology 12(3):208-215.
• Scott PM, Coldwell BB, Wiberg GS (1971), Grayanotoxins. Occurrence and analysis in honey and a comparison of toxicities in mice. Food and Cosmetics Toxicology 9(2):179-184.
• Silici S, Atayoglu AT (2015), Mad honey intoxication: A systematic review on the 1199 cases. Food and Chemical Toxicology 86:282-290.
• Ullah S, et al. (2018), Mad honey: uses, intoxicating/poisoning effects, diagnosis, and treatment. RSC Advances 8(33):18635-18646.